CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

Zydus enters agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary: Our Bureau, Mumbai Tuesday, January 7, 2025, 17:15 Hrs [IST] Zydus L ...

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...

Below is a roundup of payer-centric news headlines you may have missed during the month of December 2024 and over the ...

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...

Zydus Lifesciences has partnered with CVS Caremark to add its diabetes medications, Zituvio, Zituvimet, and Zituvimet XR, to ...

Zydus Lifesciences (including its subsidiaries/affiliates, hereafter referred to as 'Zydus'), a global innovation driven healthcare company announced that it has entered into an agreement with CVS ...

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...